Candelaria Myrna, Cetina Lucely, Garcia-Arias Alicia, Lopez-Graniel Carlos, de la Garza Jaime, Robles Elizabeth, Duenas-Gonzalez Alfonso
Division of Clinical Research, Instituto Nacional de Cancerología. Mexico City, Mexico.
World J Surg Oncol. 2006 Nov 13;4:77. doi: 10.1186/1477-7819-4-77.
Cervical cancer is the seventh most frequent cancer worldwide but more than 80% of cases occur in developing countries. Till date, radiation therapy with external beam and brachytherapy remains as the core treatment for most stages of cervical cancer. However, radiation treatment protocols and equipment modelled on the best developed countries can be seldom applied directly to developing countries owing to financial constraints and lack of qualified personnel, thus, a substantial proportion of patients do not have access to even palliative radiation therapy. Treatment options when the standard therapy is either not available or difficult to reproduce in particular settings is highly desirable with the potential to save lives that otherwise could be lost by the lack of adequate treatment. These options of treatment ideally had to have show, 1) that these are not inferior to the "standard" in terms of either survival or quality of life; 2) that these can be delivered in settings were the "standard" is not available or if available its quality is poor; and 3) that the treatment option be accepted by the population to be treated. Based on these considerations, it is obvious that cervical cancer patients, particularly those who live in countries with limited resources and therefore may not have sufficient radiation therapy resources are in need of newer therapeutical options. There is now a considerable amount of information emanating from clinical studies where surgery has a major role in treating this disease. These forms of "radiation-sparing" treatments include total mesometrial resection that could make unnecessary the use of adjuvant radiation; neoadjuvant chemotherapy that could avoid the use of adjuvant radiation in around 85% of patients and preoperative chemoradiation that could make brachytherapy dispensable. The feasibility and therapeutical value of these potential forms of management need to be prospectively evaluated.
宫颈癌是全球第七大常见癌症,但超过80%的病例发生在发展中国家。迄今为止,外照射放疗和近距离放疗仍是大多数宫颈癌阶段的核心治疗方法。然而,由于资金限制和缺乏合格人员,照搬最发达国家的放射治疗方案和设备很少能直接应用于发展中国家,因此,相当一部分患者甚至无法获得姑息性放射治疗。在标准治疗不可用或在特定环境中难以复制的情况下,非常需要有其他治疗选择,这些选择有可能挽救因缺乏适当治疗而可能失去的生命。理想情况下,这些治疗选择必须表明:1)在生存或生活质量方面,这些选择不逊色于“标准”治疗;2)这些选择可以在无法获得“标准”治疗或“标准”治疗质量较差的环境中实施;3)治疗选择能被接受治疗的人群所接受。基于这些考虑,很明显,宫颈癌患者,尤其是那些生活在资源有限国家、因此可能没有足够放疗资源的患者,需要更新的治疗选择。目前,临床研究产生了大量信息,表明手术在治疗这种疾病中起着重要作用。这些“减少放疗”的治疗形式包括全子宫系膜切除术,该手术可能使辅助放疗变得不必要;新辅助化疗可避免约85%的患者使用辅助放疗,术前放化疗可使近距离放疗变得不必要。这些潜在治疗方式的可行性和治疗价值需要进行前瞻性评估。